We analyzed newly diagnosed multiple myeloma patients, measured their CRBN levels using IHC and a commercial antibody, and showed that the IMiD therapy affects patient survival in a CRBN expression-dependent manner. The gene discussed is CRBN; the disease is plasma cell myeloma.